Notably, in the later stages of AD, the critical role of BChE has highlighted in late‐stage AD patients, who experience progressive AChE loss.[11] Consequently, the development of selective BChE inhibitors is gaining increasing attention from drug developers. This evidence concerns the gene ACHE and Alzheimer disease.